Activation of estrogen receptor beta-dependent nitric oxide signaling mediates the hypotensive effects of estrogen in the rostral ventrolateral medulla of anesthetized rats.
BACKGROUND
Apart from their well-known peripheral cardiovascular effects, emerging evidence indicates that estrogen acts as a modulator in the brain to regulate cardiovascular functions. The underlying mechanisms of estrogen in central cardiovascular regulation, however, are poorly understood. The present study investigated the cardiovascular effects of 17beta-estradiol (E2beta) in the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons are located, and delineated the engagement of nitric oxide (NO) in E2beta-induced cardiovascular responses.


METHODS
In male Sprague-Dawley rats maintained under propofol anesthesia, the changes of blood pressure, heart rate and sympathetic vasomotor tone after microinjection bilaterally into the RVLM of a synthetic estrogen, E2beta were examined for at least 120 min. The involvement of ERalpha and/or ERbeta subtypes was determined by microinjection of selective ERalpha or ERbeta agonist into bilateral RVLM. Different NO synthase (NOS) inhibitors were used to evaluate the involvement of differential of NOS isoforms in the cardiovascular effects of E2beta.


RESULTS
Bilateral microinjection of E2beta (0.5, 1, or 5 pmol) into the RVLM dose-dependently decreased systemic arterial pressure (SAP) and the power density of the vasomotor components of SAP signals, our experimental index for sympathetic neurogenic vasomotor tone. These cardiovascular depressive effects of E2beta (1 pmol) were abolished by co-injection of ER antagonist ICI 182780 (0.25 or 0.5 pmol), but not a transcription inhibitor actinomycin D (10 nmol). Like E2beta, microinjection bilaterally into the RVLM of a selective ERbeta agonist 2,3-bis(4-hydroxyphenyl) propionitrile (DPN, 1, 2, or 5 pmol) induced significant decreases in these hemodynamic parameters in a dose-dependent manner. In contrast, the selective ERalpha agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (5 pmol) did not influence the same cardiovascular parameters. Co-administration bilaterally into the RVLM of NOS inhibitor NG-nitro-L-arginine methyl ester (5 nmol) or selective inducible NOS (iNOS) inhibitor S-methylisothiourea (25 pmol), but not selective neuronal NOS inhibitor 7-nitroindazole (0.5 pmol) or endothelial NOS inhibitor N5-(1-Iminoethyl)-L-ornithine (2.5 pmol), significantly attenuated the cardiovascular depressive effects elicited by DPN (2 pmol).


CONCLUSIONS
Our results indicate that E2beta in the RVLM elicited short-term cardiovascular depressive effects via an ERbeta-dependent nontranscriptional mechanism. These vasodepressor effects of E2beta are likely to be mediated by the iNOS-derived NO in the RVLM.
Shih
Cheng-Dean
CD
Department of Pharmacy & Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung 90741, Taiwan, Republic of China. cdshih@mail.tajen.edu.tw
D000758:Anesthesia; D000818:Animals; D002319:Cardiovascular System; D004958:Estradiol / Q000378:metabolism; D047629:Estrogen Receptor beta / Q000378:metabolism*; D007022:Hypotension / Q000188:drug therapy*; D008297:Male; D008526:Medulla Oblongata / Q000187:drug effects* / Q000378:metabolism; D008953:Models, Anatomic; D008954:Models, Biological; D009046:Motor Neurons / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
D047629:Estrogen Receptor beta; D009569:Nitric Oxide; D004958:Estradiol